These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3807300)

  • 1. [Possibilities for pharmacological correction of regional osteoporosis in an unsupported extremity].
    Rogacheva IV; Poliakov AN; Volozhin AI; Stupakov GP
    Kosm Biol Aviakosm Med; 1986; 20(6):47-51. PubMed ID: 3807300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
    Need AG; Horowitz M; Walker CJ; Chatterton BE; Chapman IC; Nordin BE
    Bone; 1989; 10(1):3-6. PubMed ID: 2736154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
    Geusens P
    Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
    Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
    Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C; Agnusdei D; Gonnelli S
    Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L; Hopper JL; Larkins RG; Lichtenstein M; Buirski G; Wark JD
    Osteoporos Int; 1997; 7(1):29-35. PubMed ID: 9102059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of calcitrin and retabolil on the condition of the rat femur in hypokinesia].
    Rogacheva IV
    Patol Fiziol Eksp Ter; 1986; (4):53-6. PubMed ID: 3797077
    [No Abstract]   [Full Text] [Related]  

  • 8. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
    Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
    Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of nandrolone decanoate on rarefying bone tissue.
    Dhem A; Ars-Piret N; Waterschoot MP
    Curr Med Res Opin; 1980; 6(9):606-13. PubMed ID: 7408528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
    Need AG; Morris HA; Hartley TF; Horowitz M; Nordin BE
    Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate.
    Need AG; Nordin BE; Chatterton BE
    Osteoporos Int; 1993; 3 Suppl 1():218-22. PubMed ID: 8461566
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
    Geusens P; Dequeker J
    Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nandrolone decanoate for men with osteoporosis.
    Hamdy RC; Moore SW; Whalen KE; Landy C
    Am J Ther; 1998 Mar; 5(2):89-95. PubMed ID: 10099043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on osteoporosis VII. Effect of 17 beta-hydroxy-4-estren-3-one 17-decanoate on experimental osteoporosis.
    Robin JC; Suh OW; Ambrus JL
    Steroids; 1982 Aug; 40(2):125-32. PubMed ID: 7157449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anabolic steroids and osteoporosis.
    Dequeker J; Geusens P
    Acta Endocrinol Suppl (Copenh); 1985; 271():45-52. PubMed ID: 3865481
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prophylaxis and treatment of osteoporosis].
    Kopera H
    Klin Wochenschr; 1989 May; 67(10):557-8. PubMed ID: 2739351
    [No Abstract]   [Full Text] [Related]  

  • 18. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin.
    Aloia JF; Vaswani A; Meunier PJ; Edouard CM; Arlot ME; Yeh JK; Cohn SH
    Calcif Tissue Int; 1987 May; 40(5):253-9. PubMed ID: 2981045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of calcitonin in treating osteoporosis].
    Masyk OM; Smiian SI
    Lik Sprava; 2000; (3-4):15-8. PubMed ID: 10921250
    [No Abstract]   [Full Text] [Related]  

  • 20. ATP and LPL histochemical activity of rat cardiomyocytes and adipocytes treated with androgenic anabolic steroids.
    Delchev SD; Atanassova PK
    Folia Med (Plovdiv); 2003; 45(2):34-7. PubMed ID: 12943056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.